Aptevo Therapeutics Inc (NQ: APVO )
2.390 +0.010 (+0.42%) Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2023 Add to My Watchlist
All News about Aptevo Therapeutics Inc
Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia
June 09, 2022
Cohort 1 Combination Therapy Arm Shows 36% Remission Rate Among Response-evaluable Patients Treated to Date
Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
May 12, 2022
SEATTLE, WA / ACCESSWIRE / May 12, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology...
APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting
April 12, 2022
Preclinical Data Support Potential for APVO442 in Difficult-to-Treat Types of Prostate Cancer, Including Metastatic Castration-Resistant Disease SEATTLE, WA / ACCESSWIRE / April 12, 2022 / Aptevo...